Abstract
Ghalie et al. reviewed records of 1,378 patients who received mitoxantrone in MS clinical trials. At median cumulative dose 62.5 mg/m2 and follow-up 29 months, 2 of 1,378 patients (<0.20%) experienced congestive heart failure (CHF). Whether the incidence of CHF in MS patients will prove to be higher with greater cumulative mitoxantrone doses is not yet established. see page 909 Brassat et al. report acute leukemia in a mitoxantrone-treated patient with severe MS—the first case among 802 French mitoxantrone-treated MS patients. see page 954 Commentary by John W. Rose, MD Mitoxantrone is an important new therapy recently approved by the FDA for treatment of severe relapsing and secondary progressive multiple sclerosis. In this issue of Neurology, two articles discuss potential side effects of the drug. The article by Ghalie et al. examines the cardiotoxicity of the drug in multiple sclerosis patients demonstrating a low incidence of clinical congestive heart failure across several studies. The result of a 0.2% incidence for …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
